

HR 3299

Medicare Prescription Drug Price Negotiation Act

Congress: 108 (2003–2005, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 15, 2003

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 27, 2003)

Official Text: <https://www.congress.gov/bill/108th-congress/house-bill/3299>

Sponsor

Name: Rep. Larson, John B. [D-CT-1]

Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (19 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Case, Ed [D-HI-2]	D · HI		Nov 21, 2003
Rep. Hoeffel, Joseph M. [D-PA-13]	D · PA		Nov 21, 2003
Rep. Carson, Julia [D-IN-7]	D · IN		Nov 25, 2003
Rep. Cooper, Jim [D-TN-5]	D · TN		Nov 25, 2003
Rep. Frost, Martin [D-TX-24]	D · TX		Nov 25, 2003
Rep. Moran, James P. [D-VA-8]	D · VA		Nov 25, 2003
Rep. Emanuel, Rahm [D-IL-5]	D · IL		Dec 8, 2003
Rep. Kildee, Dale E. [D-MI-5]	D · MI		Dec 8, 2003
Rep. Miller, George [D-CA-7]	D · CA		Dec 8, 2003
Rep. Oberstar, James L. [D-MN-8]	D · MN		Dec 8, 2003
Rep. Udall, Tom [D-NM-3]	D · NM		Dec 8, 2003
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Jan 27, 2004
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Jan 27, 2004
Rep. Filner, Bob [D-CA-51]	D · CA		Jan 27, 2004
Rep. Hall, Ralph M. [R-TX-4]	R · TX		Jan 27, 2004
Rep. Hinchey, Maurice D. [D-NY-22]	D · NY		Feb 10, 2004
Rep. Larsen, Rick [D-WA-2]	D · WA		Feb 26, 2004
Rep. Grijalva, Raúl M. [D-AZ-7]	D · AZ		Jun 22, 2004
Rep. Nadler, Jerrold [D-NY-8]	D · NY		Sep 30, 2004

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 27, 2003
Ways and Means Committee	House	Referred to	Oct 20, 2003

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 15, 2003)

Medicare Prescription Drug Price Negotiation Act - Requires each participating manufacturer of a covered outpatient drug to make such drugs available for purchase by any qualified Federal health care provider, by each pharmacy, and by each provider of services, physician, practitioner, and supplier under the Medicare program at a price that the Secretary of Health and Human Services, in conjunction with the Secretary of Defense and the Secretary of Veterans Affairs, negotiates with the manufacturer. Provides that the amount of a covered outpatient drug that a participating manufacturer shall make available for purchase is equal to the sum of the aggregate amounts of the covered outpatient drug dispensed by pharmacies to Medicare beneficiaries plus those dispensed through qualified Federal health care providers.

Requires that, in conducting negotiations with participating manufacturers, the Secretary take into account the goal of promoting the development of breakthrough drugs.

Requires the United States to exclude from Government contracting and subcontracting, for a period of time, a manufacturer of drugs or biologicals that does not comply with this Act.

Directs the Secretary to establish a mechanism (such as an ombudsman) for the resolution of disputes between Medicare beneficiaries and prescription drug resellers and drug manufacturers in order to protect such beneficiaries and to ensure that: (1) prescription drug resellers are not artificially increasing prices charged to Medicare beneficiaries (above those negotiated under this Act) in places (such as rural areas) where there is less competition; and (2) such resellers are not colluding on prices in areas with more potential significant competition.

Actions Timeline

- **Oct 27, 2003:** Referred to the Subcommittee on Health.
- **Oct 20, 2003:** Referred to the Subcommittee on Health.
- **Oct 15, 2003:** Introduced in House
- **Oct 15, 2003:** Introduced in House
- **Oct 15, 2003:** Sponsor introductory remarks on measure. (CR E2041)
- **Oct 15, 2003:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 15, 2003:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 15, 2003:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.